SPRY EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026

Faruqi & Faruqi is investigating potential securities-law claims against ARS Pharmaceuticals (NASDAQ: SPRY) on behalf of investors who purchased shares between March 9 and June 24, 2026. A federal securities class action has been filed, with an October 5, 2026 deadline for investors to seek appointment as lead plaintiff. The litigation introduces reputational and potential financial-risk overhangs for ARS Pharmaceuticals, though the notice provides no details on alleged damages or underlying misconduct.

Analysis

This is not, by itself, a new fundamental datapoint; plaintiff-law-firm notices are often mechanically distributed after a sharp drawdown and should not be interpreted as evidence that liability is probable. The tradable issue is whether the underlying alleged disclosure created a durable impairment to SPRY's approval, launch, reimbursement, or cash-runway assumptions. Until the complaint identifies a credible mismatch between prior company statements and FDA correspondence, prescription data, or payer access, litigation headline risk alone is unlikely to justify a standalone short.

Near term, SPRY may face incremental retail selling and reduced institutional risk appetite into the October 5 lead-plaintiff deadline, particularly given biotech's thin liquidity and the tendency for litigation overhangs to constrain multiple recovery. The more material 1-3 month catalyst path is any amended complaint, company response, regulatory update, or revised commercial guidance; these events can force management to disclose information not contained in the initial notice. A secondary effect is higher expected D&O and legal expense, but that matters economically only if cash needs accelerate ahead of commercial traction.

Contrarian framing: litigation-driven weakness can become an entry point if the selloff is disconnected from the value of neffy commercialization and the company retains sufficient liquidity through its next operating milestones. Conversely, a short becomes more compelling only if independent evidence shows launch execution is below the level embedded in consensus revenue estimates or that regulatory labeling/access assumptions have deteriorated. Falsify a cautious stance with a formal FDA or payer-related adverse development, a material guidance cut, or a cash-runway update implying financing before expected revenue inflection.

Key Decisions for Investors

• No new directional position solely on this notice; treat SPRY as an event-risk watch item through the October 5 deadline, as the legal notice lacks independently verifiable fundamental information.
• For existing long exposure, reduce gross or hedge over the next 2-3 weeks with defined-risk puts only if implied volatility remains below the stock's post-event realized volatility; avoid naked short exposure in a high-beta biotech.
• Set a short trigger rather than pre-positioning: reassess for a 1-3 month short if SPRY cuts launch/revenue guidance, reports materially weaker prescription or payer-access progress than consensus, or signals a financing need before commercial ramp. Cover on evidence that liquidity extends through the next key launch milestone.
• Set a long trigger on litigation-induced dislocation: consider a small, staged long only after verifying cash runway and commercialization metrics, with risk defined below the post-disclosure low and upside tied to normalization of revenue expectations over 6-18 months.